Literature DB >> 6370067

Drugs five years later. Cisplatin.

P J Loehrer, L H Einhorn.   

Abstract

Cisplatin is a metal coordination compound that was approved for clinical use in treating testicular cancer 5 years ago. Although early trials showed marked gastrointestinal and renal toxicities, treatment-related morbidity has been significantly alleviated with modern antiemetic therapy and adequate pretreatment hydration. More recent clinical studies of cisplatin have shown a broad range of activity and provide a better understanding of the drug's pharmacology, mechanism of action, and toxicity. Variations in the dosage and mode of administration as well as development of cisplatin analogues are being currently studied.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6370067     DOI: 10.7326/0003-4819-100-5-704

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  198 in total

1.  The effect of chromatin structure on cisplatin damage in intact human cells.

Authors:  N P Davies; L C Hardman; V Murray
Journal:  Nucleic Acids Res       Date:  2000-08-01       Impact factor: 16.971

2.  Mitaplatin increases sensitivity of tumor cells to cisplatin by inducing mitochondrial dysfunction.

Authors:  Xue Xue; Song You; Qiang Zhang; Yan Wu; Guo-Zhang Zou; Paul C Wang; Yu-Liang Zhao; Yan Xu; Lee Jia; Xiaoning Zhang; Xing-Jie Liang
Journal:  Mol Pharm       Date:  2012-02-13       Impact factor: 4.939

3.  Global phosphoproteome profiling reveals unanticipated networks responsive to cisplatin treatment of embryonic stem cells.

Authors:  Alex Pines; Christian D Kelstrup; Mischa G Vrouwe; Jordi C Puigvert; Dimitris Typas; Branislav Misovic; Anton de Groot; Louise von Stechow; Bob van de Water; Erik H J Danen; Harry Vrieling; Leon H F Mullenders; Jesper V Olsen
Journal:  Mol Cell Biol       Date:  2011-10-17       Impact factor: 4.272

4.  Roles of volume-sensitive Cl- channel in cisplatin-induced apoptosis in human epidermoid cancer cells.

Authors:  T Ise; T Shimizu; E L Lee; H Inoue; K Kohno; Y Okada
Journal:  J Membr Biol       Date:  2005-06       Impact factor: 1.843

5.  Repair synthesis by human cell extracts in DNA damaged by cis- and trans-diamminedichloroplatinum(II).

Authors:  J Hansson; R D Wood
Journal:  Nucleic Acids Res       Date:  1989-10-25       Impact factor: 16.971

6.  Mutagenic and genotoxic effects of DNA adducts formed by the anticancer drug cis-diamminedichloroplatinum(II).

Authors:  K J Yarema; S J Lippard; J M Essigmann
Journal:  Nucleic Acids Res       Date:  1995-10-25       Impact factor: 16.971

Review 7.  A Systematic Review of Strategies to Prevent Cisplatin-Induced Nephrotoxicity.

Authors:  Daniel J Crona; Aimee Faso; Tomohiro F Nishijima; Kathleen A McGraw; Matthew D Galsky; Matthew I Milowsky
Journal:  Oncologist       Date:  2017-04-24

8.  Efficient copper-based DNA cleavers from carboxylate benzimidazole ligands.

Authors:  Víctor A Barrera-Guzmán; Edgar O Rodríguez-Hernández; Naytzé Ortíz-Pastrana; Ricardo Domínguez-González; Ana B Caballero; Patrick Gamez; Norah Barba-Behrens
Journal:  J Biol Inorg Chem       Date:  2018-08-03       Impact factor: 3.358

9.  In vivo screening models of cisplatin-resistant human lung cancer cell lines using SCID mice.

Authors:  Y Heike; M Takahashi; T Ohira; H Arioka; Y Funayama; K Nishio; H Ogasawara; N Saijo
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

10.  Cisplatin pharmacokinetics in a child receiving peritoneal dialysis.

Authors:  Judit Sebestyen; Uttam Garg; Karen B Lewing; Bradley A Warady; Susan Abdel-Rahman; Douglas L Blowey
Journal:  Pediatr Nephrol       Date:  2010-01-19       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.